New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
19:03 EDTMNOVMedicNova receives notice of allowance for new patent covering MN-001, MN-002
MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of nonalcoholic fatty liver disease. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032. The allowed claims cover a method of treating nonalcoholic fatty liver disease and a method of reducing liver inflammation in nonalcoholic fatty liver disease using MN-001 or MN-002. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
08:12 EDTMNOVMediciNova announces FDA approval of second Phase 2 protocol for MN-001 in NASH
MediciNova announced that FDA has approved a second protocol for a clinical trial evaluating MN-001 for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use